FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers

    -   Nerviano Medical Sciences (NMS): Green Light From the FDA for the
        CDC7 Inhibitor

    NERVIANO, Italy, Feb. 10 /CNW/ - Nerviano Medical Sciences (NMS) has
secured Food and Drug Administration (FDA) approval to conduct for the first
time clinical trials of a novel antitumoral agent. The drug blocks Cdc7, a
protein that is responsible for the uncontrolled proliferation of cancer
cells. The preclinical data, recently published on the prestigious journal
Nature Chemical Biology
demonstrate that inhibition of Cdc7 induces tumor cell death and blocks the
growth of various types of cancer in experimental animal models.
    The FDA approval will allow to conduct clinical phase I trials in cancer
patients. "The news that the FDA has approved the clinical experimentation of
our Cdc7 inhibitor - explains Dr. Francesco Colotta, NMS Oncology VP - first
of all represents an acknowledgment of the quality and innovation of Italian
research in the field of oncology. The discovery of this new drug results
exclusively from the efforts of our investigators at the NMS R&D Site in
Nerviano; thanks to their competence and passion we will be the first in the
world to explore this new antitumor mechanism".

    About Nerviano Medical Sciences (NMS)

    Nerviano Medical Sciences is the largest pharmaceutical R&D facility in
Italy and one of the largest oncology-focused, integrated discovery and
development companies in Europe. Research activities in Nerviano generate on
average two clinical candidate molecules per year. NMS takes advantage of
strategic alliances with biotechnology as well as pharmaceutical companies to
secure its long term business sustainability. The Company has already
finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers
Squibb Co., Genentech Inc. as well as with several biotech companies and
academic institutions.

For further information:

For further information: Nerviano Medical Sciences, Maria D'Acquino, tel
+39(0)331-581013, mob. +39(0)335-1863051, maria.dacquino@nervianoms.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890